ALT — Altimmune Inc
NASDAQ · Healthcare · Biotechnology
$3.29
+$0.20 (+6.48%)
Altimmune Inc (ALT) is a biotechnology company listed on NASDAQ. It is led by Jerome Benedict Durso, based in 910 Clopper Road, Gaithersburg, MD, United States, 20878, with about 57 employees. Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.
Latest reported ALT revenue for 2025-09-30 was $5.0K. Net income was -$60.7M. Revenue was up 0.0% from 2025-06-30 to 2025-09-30. ALT currently screens at market cap $527.0M.
Use this ALT page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the ALT quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the ALT SEC filings page. Lician reads the product cache first so this HTML stays unique to Altimmune Inc even when a live quote feed is slow.
About Altimmune Inc
Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.
ALT Key Statistics
Market Cap
$527.02M
Volume
3.80M
Previous Close
$3.11
Day Range
$3.11 – $3.23
EPS
-$1.34
Revenue
$20.00K
Net Income
-$95.06M
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
-95.3%
Profit Margin
-475295.0%
Employees
57
ALT Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $20.00K | $426.00K | -$68.00K | $4.41M |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$95.06M | -$88.45M | -$84.71M | -$97.09M |
| EPS (Diluted) | -$1.34 | -$1.66 | -$1.81 | -$2.35 |
Total Assets
$139.31M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$36.93M
Operating Cash Flow
-$79.85M
Free Cash Flow
$0.00
Altimmune Inc Company Information
- Chairman, CEO & President
- Jerome Benedict Durso
- Headquarters
- 910 Clopper Road, Gaithersburg, MD, United States, 20878
- Website
- altimmune.com
- Phone
- 240 654 1450
- IPO / Founded
- 2005-10-06
- Sector
- Healthcare
- Industry
- Biotechnology